GlaxoSmithKline: EMEA To Review Profile Of Avandia (Rosiglitazone)

9th Jul 2010 10:09

LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), a global healthcare group confirmed Friday that on behalf of the European Medicines Agency or EMEA, the Committee for Medicinal Products for Human Use or CHMP, is to review the benefit/risk profile of Avandia (rosiglitazone). MAIN FACTS: -This follows the recent publication of an observational study and a meta-analysis regarding Avandia since the CHMP last reviewed the product in early 2010. -All data generated by the company has previously been submitted to the EMEA. -The Committee is expected to review and discuss the data with the company during its scheduled meeting on July 19-22. -Shares at 0906 GMT down 19.50 pence, or 1.71%, at 1122.50 pence. -By Zechariah Hemans, Dow Jones Newswires; 44-20-7842-9411; [email protected] (END) Dow Jones Newswires July 09, 2010 05:09 ET (09:09 GMT)